H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Compass Therapeutics today and set a price target of $24.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Compass Therapeutics’ promising preclinical asset, CTX-10726. The data presented at SITC ’25 indicates that CTX-10726, a novel bispecific antibody targeting PD-1 and VEGF, shows best-in-class potential in treating solid tumors. The preclinical results demonstrate that CTX-10726 effectively inhibits its targets with high affinity and exhibits robust anti-tumor activity, outperforming existing competitors in the market.
Moreover, the molecule’s pharmacokinetics in non-human primates suggest a favorable safety profile, reducing potential risks. As the VEGF and PD-1 markets grow increasingly competitive, CTX-10726’s ability to match or surpass the performance of other drugs like ivonescimab and bevacizumab positions it as a potential leader in its class. The anticipation of further clinical development, including a Phase 1 study in early 2026, adds to the optimism surrounding Compass Therapeutics’ future prospects.
In another report released on November 5, LifeSci Capital also maintained a Buy rating on the stock with a $10.00 price target.